石藥(01093.HK)夥康諾亞(02162.HK)研發神經系統藥
石藥集團(01093.HK)公佈,其全資附屬津曼特生物與康諾亞生物(02162.HK)全資附屬成都康諾亞已訂立戰略聯盟協議,雙方應共同確定、研究、開發和商業化一種或多種神經系統疾病產品。津曼特主要負責合作產品的臨牀開發和商業化,成都康諾亞主要負責合作產品的臨牀前研發。
公司相信,戰略聯盟將進一步加強集團與康諾亞生物的合作,雙方將進一步利用其各自優勢,協調其資源以共同推動神經系統疾病有關藥物的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.